Medicare spending per beneficiary averages roughly $16,000 to $20,000 per year, depending on how costs are measured and which parts of the program are included. Total Medicare spending reached $1.118 trillion in 2024, a 7.8% increase over the prior year, covering more than 67 million enrollees. That per-person figure varies dramatically based on where you live, what type of coverage you have, and your health status.
What the Average Actually Includes
The 2025 Medicare Trustees Report projects total average incurred costs per beneficiary at $19,868 for 2026. This figure combines hospital care (Part A), outpatient and physician services (Part B), Medicare Advantage plan payments (Part C), and prescription drugs (Part D). It represents the full cost of covering one person for a year, paid through a mix of premiums, federal funding, and cost-sharing.
One thing that keeps Medicare’s overhead low compared to private insurance: administrative costs for traditional Medicare (Parts A, B, and D combined) run about 1.35% of total benefits, or roughly $147 per member per year. Medicare Advantage plans, by contrast, spend about 9 to 11% of benefits on administration, averaging around $812 per member. For comparison, public and private insurance combined average about 7% in administrative costs.
How Costs Differ by State
Geographic variation in Medicare spending is substantial. In 2020, per-beneficiary spending was highest in Florida at $13,652 and lowest in Vermont at $8,726. Those figures cover only Parts A and B for traditional Medicare enrollees, so they don’t capture the full picture, but they illustrate the gap. According to MedPAC, spending in the highest-cost metro areas runs 47% above spending in the lowest-cost areas, with a ratio of 2.17 between the maximum and minimum.
These differences reflect a combination of factors: local practice patterns (how aggressively doctors test and treat), the prevalence of chronic conditions in the population, cost of living, and how many specialists versus primary care doctors practice in an area. Two beneficiaries with identical health problems can generate very different costs depending on their zip code.
Traditional Medicare vs. Medicare Advantage
About half of all Medicare beneficiaries now enroll in Medicare Advantage plans run by private insurers. These plans often offer extra benefits like dental, vision, and hearing coverage that traditional Medicare doesn’t include. But they cost taxpayers more per person. Research from the USC Schaeffer Center found that Medicare Advantage costs the federal government 22% more per enrollee than traditional Medicare, adding up to roughly $83 billion a year in excess spending.
Part of this gap comes from how Medicare Advantage plans are paid. The federal government sets benchmark payment rates that are, on average, about 8% higher than what traditional Medicare would spend on the same population. On top of that, plans receive additional payments based on how sick their enrollees are, a system called risk adjustment. Critics argue that some plans document diagnoses more aggressively than traditional Medicare providers do, inflating their payments without reflecting genuinely sicker patients.
Who Costs the Most
Not all beneficiaries generate similar costs. The most expensive group, by far, is people who qualify for both Medicare and Medicaid (known as “dual eligibles”). These individuals tend to be low-income, have multiple chronic conditions, and need more intensive services. In 2021, Medicare spent $29,328 per dual-eligible beneficiary in the traditional program, compared to $10,907 for those who only had Medicare. That’s nearly three times as much, and dual eligibles make up a disproportionate share of total program spending.
End-of-life care also concentrates costs heavily. Beneficiaries in their final year of life account for roughly 13% to 25% of annual Medicare spending, depending on how you measure it. A widely cited estimate puts the figure at about 25%, though more recent analyses using calendar-year data place it closer to 13.5% to 21%. Either way, a small fraction of beneficiaries, about 4% of enrollees who die in a given year, drives an outsized portion of total expenditures. This isn’t necessarily wasteful. Many of these costs reflect hospitalizations and treatments for serious illnesses where the outcome was uncertain at the time care was provided.
Projected Growth Through 2033
The Medicare Trustees project per-beneficiary costs will continue climbing over the next decade. Under their intermediate (most likely) assumptions, average costs per beneficiary are expected to reach:
- 2026: $19,868
- 2030: $24,796
- 2033: $29,413
That trajectory represents roughly a 48% increase over seven years, driven by rising healthcare prices, an aging population with more complex needs, and expanded use of expensive treatments and technologies. The growth rate consistently outpaces general inflation, which is the central challenge facing the program’s long-term finances. The Part A trust fund, which covers hospital costs, faces periodic solvency deadlines that Congress has historically addressed through a mix of tax adjustments and payment reforms.
What Drives Per-Beneficiary Costs Up
Several forces push spending higher each year. Hospital and physician prices rise faster than inflation. New drugs, particularly specialty medications for cancer and autoimmune diseases, add significant costs. And the Medicare population itself is getting sicker on average, as the baby boom generation ages into their 70s and 80s, when chronic disease management becomes more intensive.
Prescription drug spending highlights this dynamic clearly. Beneficiaries who receive low-income subsidies (about 40% of Part D enrollees) account for 55% of total Part D drug spending, with average per-person drug costs of $3,600 compared to $1,800 for those without subsidies. Sicker, lower-income enrollees use more medications at higher doses, and the costs compound across the program.
Policy changes have tried to slow growth. The Inflation Reduction Act gave Medicare the authority to negotiate prices on certain high-cost drugs for the first time, and it capped out-of-pocket drug spending for Part D enrollees at $2,000 per year starting in 2025. Whether these measures meaningfully bend the per-beneficiary spending curve will take several years to assess.